New Data Show Cervical Cancer Vaccine Provided Significant Protection Through 3 Years

OncologyONCOLOGY Vol 21 No 7
Volume 21
Issue 7

The New England Journal of Medicine recently published results from two phase III studies of Merck's cervical cancer vaccine, Gardasil [quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine].

The New England Journal of Medicine recently published results from two phase III studies of Merck's cervical cancer vaccine, Gardasil [quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine]. In the first study, Gardasil provided 100% protection against cervical, vaginal, and vulvar diseases caused by the four HPV types the vaccine is designed to protect against—HPV types 6, 11, 16, and 18. In the second study, the vaccine provided 98% protection against advanced cervical precancers caused by the two primary cancer-causing HPV types—HPV 16 and 18. These significant results, observed in 15- to 26-year-old women who were not infected with the relevant HPV types when they began the study, were sustained through an average of 3 years of participation in the trials, including an additional year of follow-up since data were presented to the US Food and Drug Administration (FDA) for approval of the vaccine (N Engl J Med 356:1915-1927, 2007).

Decreasing the Burden

"In these two studies, Gardasil demonstrated significant protection against serious HPV-related diseases, including high-grade cervical precancers, in women not previously exposed to the relevant HPV types targeted by the vaccine," said Kevin Ault, md, associate professor, division of gynecologic oncology, department of gynecology and obstetrics, Emory University School of Medicine, Atlanta. "Widespread immunization of 11- to 26-year-old girls and women with Gardasil, along with continued screening, will help decrease the burden of cervical cancer and other HPV-related diseases."

It is estimated that in 2007, cervical cancer will strike more than 11,000 women in the US and nearly 500,000 women around the world. Gardasil helps protect against the four HPV types that cause the most disease, including 70% of cervical cancer cases and 90% of cases of genital warts. All four types cause a large number of "abnormal" Pap test results and low-grade cervical lesions.

Related Videos
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Related Content